Bristol Myers Pops As Key Payout For Celgene Investors Looks Secure

Bristol Myers Pops As Key Payout For Celgene Investors Looks Secure

Bristol Myers Squibb stock jumped Tuesday after the pharmaceutical giant submitted its application for Food and Drug Administration approval of a key cancer treatment called bb2121.